Previous 10 | Next 10 |
Axonics Modulation Technologies, Inc. (AXNX) Q1 2020 Earnings Conference Call May 05, 2020 04:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Particip...
Axonics Modulation Technologies (NASDAQ: AXNX ) prices public offering of 4M common shares at $32.50, yielding gross proceeds of ~$130M. More news on: Axonics Modulation Technologies, Inc., , Tech stocks news, Read more ...
Image source: The Motley Fool. Axonics Modulation Technlogs INC (NASDAQ: AXNX) Q1 2020 Earnings Call May 05, 2020 , 4:30 p.m. ET Operator Continue reading
Gainers: MELI +18.9% . VAPO +15.9% . CLW +10.0% . NTNX +10.0% . AXNX +9.2% . More news on: MercadoLibre, Inc., Vapotherm, Inc., Clearwater Paper Corporation, Stocks on the move, , Read more ...
Axonics Modulation Technologies (NASDAQ: AXNX ): Q1 GAAP EPS of -$0.43 beats by $0.15 . More news on: Axonics Modulation Technologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the firs...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today the appointment of Michael H....
New Implantable Neurostimulator Decreases Recharge Interval to Only Once a Month Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (“SNM”) devices for the...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financia...
Axonics Modulation Technologies (NASDAQ: AXNX ) submits a supplemental premarket approval (PMA) to the FDA to gain full-body magnetic resonance imaging (MRI) conditional labeling for 3.0T MRI scans. More news on: Axonics Modulation Technologies, Inc., Healthcare stocks news, Read mor...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...